Review
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 27, 2025; 17(6): 106932
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.106932
Oncohepatology: Navigating liver injury in the era of modern cancer therapy
Shuo-Feng Li, Xu Ouyang, Shi Feng, Ming-Zhong Wan, Kai-Nan Zhou, Bo-Yuan Wen, Yu-Ze Yin, Hang Yi, Xin-Yuan Chen
Shuo-Feng Li, Shi Feng, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Xu Ouyang, Ming-Zhong Wan, Shantou University, Shantou 515063, Guangdong Province, China
Kai-Nan Zhou, Peking University Health Science Center, Beijing 100191, China
Bo-Yuan Wen, Hang Yi, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Yu-Ze Yin, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Xin-Yuan Chen, Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Co-corresponding authors: Hang Yi and Xin-Yuan Chen.
Author contributions: Li SF, Ouyang X, Feng S, Wan MZ, Zhou KN, Wen BY, and Yin YZ reviewed the literature and wrote the first draft of the paper; Li SF, Ouyang X, and Feng S contributed to searching the literature; Zhou KN, Wen BY, and Yin YZ completed the table and edited the paper; Yi H and Chen XY contributed to writing the paper, conceived the idea, edited it extensively, and made equal contributions as co- corresponding authors. All authors approved the final version manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xin-Yuan Chen, Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. chenxinyuan_pumc@163.com
Received: March 16, 2025
Revised: April 24, 2025
Accepted: June 3, 2025
Published online: June 27, 2025
Processing time: 103 Days and 3.7 Hours
Core Tip

Core Tip: Oncohepatology has emerged as a vital subspecialty bridging oncology and hepatology to address liver injury associated with modern cancer therapies. This manuscript unveils mechanisms of hepatic damage caused by chemotherapy, targeted therapy, immunotherapy, and radiation. It further highlights elevated risks of adverse events during cancer treatment in patients with preexisting liver diseases, thereby underscoring the necessity for tailored clinical management. Integrating diagnostic biomarkers and hepatoprotective strategies, this work also proposes a comprehensive roadmap for early detection and management of cancer treatment-induced hepatotoxicity.